Advertisement
Advertisement
INSM
Insmed, Inc.
115.63
USDSponsored
-2.04
-1.73%
Sep 29, 16:00 UTC -4
Closed
After-Market
116.17
+0.54
+0.46%
INSM Earnings Reports
Positive Surprise Ratio
INSM beat 17 of 43 last estimates.
40%
Next Report
Date of Next Report
Oct 28, 2026
Estimate for Q3 26 (Revenue/ EPS)
$514.48M
/-$0.38
Implied change from Q2 26 (Revenue/ EPS)
+20.92%
/+533.33%
Implied change from Q3 25 (Revenue/ EPS)
+261.44%
/-78.29%
Insmed, Inc. earnings per share and revenue
On Aug 06, 2026, INSM reported earnings of -0.06 USD per share (EPS) for Q2 26, beating the estimate of -0.79 USD, resulting in a 92.50% surprise. Revenue reached 425.49 million, compared to an expected 400.69 million, with a 6.19% difference. The market reacted with a +33.86% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 10 analysts forecast an EPS of -0.38 USD, with revenue projected to reach 514.48 million USD, implying an increase of 533.33% EPS, and increase of 20.92% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
>+10,000.00%
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
FAQ
What were Insmed, Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Insmed, Inc. reported EPS of -$0.06, beating estimates by 92.5%, and revenue of $425.49M, 6.19% above expectations.
How did the market react to Insmed, Inc.'s Q2 2026 earnings?
The stock price moved up 33.86%, changed from $99.02 before the earnings release to $132.55 the day after.
When is Insmed, Inc. expected to report next?
The next earning report is scheduled for Oct 28, 2026.
What are the forecasts for Insmed, Inc.'s next earnings report?
Based on 10
analysts, Insmed, Inc. is expected to report EPS of -$0.38 and revenue of $514.48M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.